Among these, variants in specific codons of the Kirsten RAS (KRAS) oncogene are of particular interest due to their ability to predict tumor response to anti-epidermal growth factor receptor (EGFR)-targeted therapies [2]. The gene discussed is KRAS; the disease is neoplasm.